Clinical Characteristics And Treatment Outcomes In Lung Cancer Patients With Fgfr Genes Alterations

Background: Lung cancer (LG) is characterized by numerous genomic alterations although so far targeted agents have been approved only for some of them. FGFR genes alterations have been described in lung cancer patients but clinical characteristics and treatment outcomes are not well known yet. Methods: A retrospective review of advanced LG patients with FGFR alterations based on tissue or plasma NGS was performed to describe clinical characteristics and treatment outcomes. Results: Clinical characteristics of 47 identified were similar to other types of LG (61.7% male, median age 68 y, 70.2% former smokers, 46.8% ECOG 0, 72.3% stage IV). Adenocarcinoma was the most frequent subtype (59.6%), then squamous (21.8%) and small cell (6.4%). PD-L1 >50% in 43.8% of patients and TMB was <10 in 58.3%. FGFR alterations were described in tissue NGS in 21 patients and “liquid" biopsy in 27 patients. In two patients NGS were realized simultaneously on tissue and plasma. Clinical records of 41 patients were available. The table shows the type of first-line treatment and response rates in 35 advanced patients. Only 12 patients received second-line of treatment. mOS was 25.0 months (CI 95%: 17.1–32.8) and mSLP was 9.0 months (CI 95%: 0.0–19.4). Table 218PType of treatmentn (%)Progression (%)Stable disease (%)Complete response (%)CT21 (44.7)16 (45.7)3 (8.5)0IT9 (21.5)3 (8.5)5 (14.2)1 (2.8)CT + IT5 (10.6)4 (11.4)00FGFR mutations were the most frequent molecular alterations (FGFR1 (48.9%), FGFR2 (27.7%) and FGFR3 (19.1%)), although only 38.5% were described as pathogenic (50% in tissue and 50% in plasma). Amplification were found in 29.8% of patients (85.8% in tissue and in 14.2% plasma). FGFR was associated to EGFR, PIK3CA and KRAS mutations in 27 patients. No correlation was found between the type of FGFR alteration and survival in the univariant analysis. Variants of FGFR did not have association with sex, ECOG, histology, status of smoking, PD-L1, TMB and type of treatment. Open table in a new tab FGFR mutations were the most frequent molecular alterations (FGFR1 (48.9%), FGFR2 (27.7%) and FGFR3 (19.1%)), although only 38.5% were described as pathogenic (50% in tissue and 50% in plasma). Amplification were found in 29.8% of patients (85.8% in tissue and in 14.2% plasma). FGFR was associated to EGFR, PIK3CA and KRAS mutations in 27 patients. No correlation was found between the type of FGFR alteration and survival in the univariant analysis. Variants of FGFR did not have association with sex, ECOG, histology, status of smoking, PD-L1, TMB and type of treatment. Conclusions: Our cohort did not show that FGFR genes alterations confer distinct clinical characteristics in LG patients. However, much more investigation is needed. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.